New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

(marketscreener.com) Results show overall confirmed objective response rate of 33%, disease control rate of 92%, and median progression-free survival of 9.6 monthsData support further investigation of zanidatamab in combination with palbociclib and fulvestrant as a potential chemotherapy-free therapeutic option for patients with HER2-positive metastatic breast...https://www.marketscreener.com/quote/stock/ZYMEWORKS-INC-34658200/news/New-Clinical-Data-for-Zanidatamab-in-HER2-HR-Metastatic-Breast-Cancer-Presented-Today-at-2022-SAB-42514547/?utm_medium=RSS&utm_content=20221209